Regenerative medicine is generating growing interest in terms of research and market investment, according to a data analysis announced June 18 by Frost & Sullivan.

Small molecule biomarkers, cell therapy, gene therapy and tissue engineering have all geared up in regenerative medicine in recent years, said Frost & Sullivan Healthcare senior research analyst Aiswariya Chidambaram, who wrote the report.

"Cell-based models are anticipated to speed-up the discovery of new molecules and biologics, the safety and toxicity testing of newly discovered drugs, and provide a solid understanding of underlying disease mechanisms,” said Chidambaramin in a press release. "As more pharma companies acquire profitable cell therapy companies or strategically invest in emerging cell and advanced therapy organisations, the consolidation wave is likely to rise higher in the industry."

Some of the challenges in the industry were noted as a lack of “consensus and strategic interaction” between players. Chidambaram asserted that federal agencies need to cinch up redundancy and ease regulatory protocol, especially in America. An official interface with the FDA, U.S. Centers for Medicare & Medicaid Services (CMS), National Institutes of Health (NIH), National Center for Health Statistics (NCHS) and others may need to be established in order for regenerative medicine to get a real foot hold.

"On the whole, governments all over the world are expected to implement legislative policies favouring the establishment of centres of excellence, manufacturing infrastructure, research networks and economic diversification to support the development of regenerative medicine," Chidambaram stated.